Monophosphoryl lipid A induces bone marrow precursor cells to differentiate into myeloid-derived suppressor cells

Chen,Jie; Sun,Baomu; Zhao,Xiuhua; Liang,Dong; Liu,Junxia; Huang,Yong; Lei,Wanke; Chen,Maomao; Sun,Weimin

doi:10.3892/mmr.2013.1653

Monophosphoryl lipid A induces bone marrow precursor cells to differentiate into myeloid-derived suppressor cells

Authors:
- Jie Chen
- Baomu Sun
- Xiuhua Zhao
- Dong Liang
- Junxia Liu
- Yong Huang
- Wanke Lei
- Maomao Chen
- Weimin Sun
View Affiliations

Affiliations: Department of Ophthalmology, 117th Hospital of PLA, Hangzhou, Zhejiang 310013, P.R. China, Department of Integrated Chinese Traditional and Western Medicine, Eastern Hepatobiliary Surgical Hospital, Second Military Medical University, Shanghai 200433, P.R. China, Department of Centre for Disease Prevention and Control, Chengdu Military Region, Chengdu, Sichuan 610021, P.R. China, Department of Stomatology, The People's Hospital of Mianzhu, Mianzhu, Sichuan 618200, P.R. China, National Key Laboratory of Medical Immunology & Institute of Immunology, Second Military Medical University, Shanghai 200433, P.R. China
Published online on: August 27, 2013 https://doi.org/10.3892/mmr.2013.1653
Pages: 1074-1078

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Myeloid-derived suppressor cells (MDSCs) and dendritic cells (DCs) are important in the immune response. In vitro, DCs are derived from myeloid precursors by stimulation with granulocyte macrophage colony‑stimulating factor and interleukin‑4. Previous studies demonstrated that lipopolysaccharide (LPS) in combination with interferon‑γ inhibited DC development but enhanced MDSC functions. Monophosphoryl lipid A (MPL), derived from LPS, is a unique immunomodulatory Toll‑like receptor 4 agonist. In the present study, MPL was used to disturb DC differentiation from myeloid precursors and it was observed that prolonged stimulation with MPL led to the accumulation of MDSCs in vitro and in vivo. In conclusion, it was demonstrated that stimulation by MPL from the beginning of cell differentiation disturbed the development of DCs and led to the accumulation of MDSCs.

View Figures

View References

1	Casella CR and Mitchell TC: Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci. 65:3231–3240. 2008. View Article : Google Scholar : PubMed/NCBI
2	Michaud JP, Hallé M, Lampron A, et al: Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer’s disease-related pathology. Proc Natl Acad Sci USA. 110:1941–1946. 2013.PubMed/NCBI
3	Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 9:271–296. 1991. View Article : Google Scholar : PubMed/NCBI
4	Banchereau J and Steinman RM: Dendritic cells and the control of immunity. Nature. 392:245–252. 1998. View Article : Google Scholar
5	Bronte V and Zanovello P: Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 5:641–654. 2005. View Article : Google Scholar : PubMed/NCBI
6	Rodríguez PC and Ochoa AC: Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev. 222:180–191. 2008.PubMed/NCBI
7	Youn JI, Nagaraj S, Collazo M and Gabrilovich DI: Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 181:5791–5802. 2008. View Article : Google Scholar : PubMed/NCBI
8	Kusmartsev S, Nefedova Y, Yoder D and Gabrilovich DI: Antigen-specific inhibition of CD8⁺ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol. 172:989–999. 2004.PubMed/NCBI
9	Schmielau J and Finn OJ: Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 61:4756–4760. 2001.
10	Kusmartsev S, Nagaraj S and Gabrilovich DI: Tumor-associated CD8⁺ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol. 175:4583–4592. 2005.PubMed/NCBI
11	Szuster-Ciesielska A, Hryciuk-Umer E, Stepulak A, Kupisz K and Kandefer-Szerszeń M: Reactive oxygen species production by blood neutrophils of patients with laryngeal carcinoma and antioxidative enzyme activity in their blood. Acta Oncol. 43:252–258. 2004. View Article : Google Scholar
12	Waris G and Ahsan H: Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog. 5:142006. View Article : Google Scholar : PubMed/NCBI
13	Mantovani G, Macciò A, Madeddu C, et al: Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. J Mol Med (Berl). 81:664–673. 2003. View Article : Google Scholar
14	Agostinelli E and Seiler N: Non-irradiation-derived reactive oxygen species (ROS) and cancer: therapeutic implications. Amino Acids. 31:341–355. 2006. View Article : Google Scholar : PubMed/NCBI
15	Yang R, Cai Z, Zhang Y, Yutzy WH, Roby KF and Roden RB: CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1⁺CD11b⁺ myeloid cells. Cancer Res. 66:6807–6815. 2006. View Article : Google Scholar : PubMed/NCBI
16	Huang B, Pan PY, Li Q, et al: Gr-1⁺CD115⁺ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66:1123–1131. 2006.
17	Lutz MB, Kukutsch NA, Menges M, Rössner S and Schuler G: Culture of bone marrow cells in GM-CSF plus high doses of lipopolysaccharide generates exclusively immature dendritic cells which induce alloantigen-specific CD4 T cell anergy in vitro. Eur J Immunol. 30:1048–1052. 2000. View Article : Google Scholar
18	Greifenberg V, Ribechini E, Rössner S and Lutz MB: Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur J Immunol. 39:2865–2876. 2009. View Article : Google Scholar : PubMed/NCBI
19	Liu C, Zhang C, Lu H, et al: Poly(I:C) induce bone marrow precursor cells into myeloid-derived suppressor cells. Mol Cell Biochem. 358:317–323. 2011. View Article : Google Scholar : PubMed/NCBI
20	Baldridge JR and Crane RT: Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods. 19:103–107. 1999. View Article : Google Scholar : PubMed/NCBI
21	Ulrich JT and Myers KR: Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotechnol. 6:495–524. 1995. View Article : Google Scholar : PubMed/NCBI
22	Tsujimoto H, Efron PA, Matsumoto T, et al: Maturation of murine bone marrow-derived dendritic cells with poly(I:C) produces altered TLR-9 expression and response to CpG DNA. Immunol Lett. 107:155–162. 2006. View Article : Google Scholar : PubMed/NCBI
23	Zhang M, Tang H, Guo Z, et al: Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. Nat Immunol. 5:1124–1133. 2004. View Article : Google Scholar : PubMed/NCBI
24	Tang H, Guo Z, Zhang M, Wang J, Chen G and Cao X: Endothelial stroma programs hematopoietic stem cells to differentiate into regulatory dendritic cells through IL-10. Blood. 108:1189–1197. 2006. View Article : Google Scholar : PubMed/NCBI
25	Xia S, Guo Z, Xu X, Yi H, Wang Q and Cao X: Hepatic microenvironment programs hematopoietic progenitor differentiation into regulatory dendritic cells, maintaining liver tolerance. Blood. 112:3175–3185. 2008. View Article : Google Scholar
26	Li Q, Guo Z, Xu X, Xia S and Cao X: Pulmonary stromal cells induce the generation of regulatory DC attenuating T-cell-mediated lung inflammation. Eur J Immunol. 38:2751–2761. 2008. View Article : Google Scholar : PubMed/NCBI
27	Sánchez-Sánchez N, Riol-Blanco L and Rodríguez-Fernández JL: The multiple personalities of the chemokine receptor CCR7 in dendritic cells. J Immunol. 176:5153–5159. 2006.PubMed/NCBI
28	Pan PY, Wang GX, Yin B, et al: Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood. 111:219–228. 2008. View Article : Google Scholar : PubMed/NCBI
29	Sinha P, Clements VK, Fulton AM and Ostrand-Rosenberg S: Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 67:4507–4513. 2007. View Article : Google Scholar : PubMed/NCBI
30	Serafini P, Carbley R, Noonan KA, Tan G, Bronte V and Borrello I: High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 64:6337–6343. 2004. View Article : Google Scholar
31	Bunt SK, Yang L, Sinha P, Clements VK, Leips J and Ostrand-Rosenberg S: Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67:10019–10026. 2007. View Article : Google Scholar : PubMed/NCBI
32	Gabrilovich D, Ishida T, Oyama T, et al: Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 92:4150–4166. 1998.
33	Kusmartsev S and Gabrilovich DI: STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol. 174:4880–4891. 2005. View Article : Google Scholar : PubMed/NCBI
34	Movahedi K, Guilliams M, Van den Bossche J, et al: Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 111:4233–4244. 2008. View Article : Google Scholar : PubMed/NCBI
35	Terabe M, Matsui S, Park JM, et al: Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med. 198:1741–1752. 2003. View Article : Google Scholar
36	Cluff CW: Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol. 667:111–123. 2010. View Article : Google Scholar
37	Abdi K, Singh NJ and Matzinger P: Lipopolysaccharide-activated dendritic cells: ‘exhausted’ or alert and waiting? J Immunol. 188:5981–5989. 2012.